Novo Nordisk's Wegovy Pill Success Raises Questions on Sustainability

What happened

Novo Nordisk's Wegovy pill has achieved over 2 million prescriptions since its January launch, outperforming Eli Lilly's Foundayo, leading the company to raise its 2026 financial targets. However, despite this strong launch, the DeepValue master report highlights that Novo Nordisk continues to face significant structural challenges, including losing US GLP-1 volume market share and experiencing unprecedented pricing pressure. The raised targets are also suspect as they likely include a one-time $4.2 billion 340B revenue recognition in Q1 2026, which inflates reported sales without reflecting underlying demand. The company's own guidance still expects a 4-12% sales decline in 2026, indicating that the Wegovy pill's success may not be sufficient to offset the broader competitive and pricing headwinds. Investors should view the positive news with skepticism until future filings confirm that pricing and share losses are stabilizing without further concessions.

Implication

The Wegovy pill launch provides a potential volume lever, but it may not be enough to offset the ongoing net price compression and share loss to Lilly. The raised 2026 targets are likely inflated by non-recurring 340B revenue, and the company's own sales decline guidance underscores persistent headwinds. Investors should demand clear disclosure in upcoming filings that isolates the one-time revenue and shows that core operating trends are improving without further price concessions. Until then, the risk/reward remains unfavorable at current valuations, with the DeepValue report suggesting an attractive entry near $40 and a WAIT rating.

Thesis delta

The article suggests a turnaround driven by the Wegovy pill's strong adoption, but the DeepValue report reveals that the underlying pricing and competitive dynamics remain challenging. The positive headlines may be overstating the fundamental improvement, as raised guidance may be artificially boosted by one-time items. The thesis shifts from potential early signs of stabilization to continued caution, as the structural issues of price compression and share loss are not yet resolved.